Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

被引:135
|
作者
Nolan, D
Upton, R
McKinnon, E
John, M
James, I
Adler, B
Roff, C
Vasikaran, S
Mallal, S [1 ]
机构
[1] Royal Perth Hosp, Dept Clin Immunol, Ctr Clin Immunol & Biomed Stat, Perth, WA 6000, Australia
[2] Murdoch Univ, Murdoch, WA 6150, Australia
[3] Royal Perth Hosp, Dept Nucl Med, Perth, WA, Australia
[4] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA, Australia
关键词
bone mineral density; HAART; indinavir; lipodystrophy syndrome; nelfinavir; protease inhibitors; osteopenia; osteoporosis; subcutaneous fat wasting;
D O I
10.1097/00002030-200107060-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and objectives: To determine the factors contributing to changes in bone mineral density (BMD) over time in HIV-infected patients receiving highly active antiretroviral therapy (HAART). Methods: Analyses of lumbar spine BMD in 183 male Caucasian participants in the Western Australian HIV Cohort study, comprising a longitudinal analysis of data from 54 patients on stable HAART regimens, and a cross-sectional analysis comparing data from 131 protease inhibitor (PI)-treated patients and 52 PI-naive (including 28 antiretroviral treatment-naive) patients. Results: Average lumbar spine BMD remained stable or increased over the time frame considered. Although there was no evidence of a change of average BMD over time in patients receiving nelfinavir (P = 0.92), there was evidence of increasing bone density in the indinavir group (average increase, 0.31 z-score per year; P < 0.001). Lower initial z-scores in the longitudinal analysis were significantly associated with lower pre-HAART BMI (P = 0.003), consistent with results of the cross-sectional analysis in which lowest BMI prior to initial dual X-ray absorptiometry scan was associated with decreased BMD (P = 0.02, overall group). Although PI therapy was also associated with decreased BMD in a univariate analysis of the cross-sectional data (P = 0.04), this effect was abrogated in a multiple linear regression analysis (P = 0.11) with lowest BMI remaining significant (P = 0.04). Conclusions: We found no evidence, overall, of accelerated bone loss in patients treated with nelfinavir- or indinavir-containing HAART regimens, and propose that indinavir therapy may be associated with an increase in bone mineral density over time. Pre-HAART BMI was an independent and powerful determinant of an individual's initial z-score in the longitudinal analysis, and adjustment for this effect in a cross-sectional analysis abrogated the association between P1 therapy and decreased lumbar spine z-score. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1275 / 1280
页数:6
相关论文
共 50 条
  • [21] High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy
    Cécile Goujard
    Mayeule Legrand
    Xavière Panhard
    Bertrand Diquet
    Xavier Duval
    Gilles Peytavin
    Isabelle Vincent
    Christine Katlama
    Catherine Leport
    Bénédicte Bonnet
    Dominique Salmon-Céron
    France Mentré
    Anne-Marie Taburet
    Clinical Pharmacokinetics, 2005, 44 : 1267 - 1278
  • [22] Antiretroviral therapy and bone mineral measurements in HIV-infected youths
    Zuccotti, Gianvincenzo
    Vigano, Alessandra
    Gabiano, Clara
    Giacomet, Vania
    Mignone, Federica
    Stucchi, Sara
    Manfredini, Valeria
    Marinacci, Francesca
    Mora, Stefano
    BONE, 2010, 46 (06) : 1633 - 1638
  • [23] Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients
    Negredo, Eugenia
    Warriner, Amy H.
    CURRENT OPINION IN HIV AND AIDS, 2016, 11 (03) : 351 - 357
  • [24] Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women
    Kosel, BW
    Beckerman, KP
    Hayashi, S
    Homma, M
    Aweeka, FT
    AIDS, 2003, 17 (08) : 1195 - 1199
  • [25] Chronic Viral Hepatitis Is Associated With Low Bone Mineral Density in HIV-Infected Patients, ANRS CO 3 Aquitaine Cohort
    Lawson-Ayayi, Sylvie
    Cazanave, Charles
    Kpozehouen, Alphonse
    Barthe, Nicole
    Mehsen, Nadia
    Hessamfar, Mojgan
    Dupon, Michel
    Dabis, Francois
    Neau, Didier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (04) : 430 - 435
  • [26] Reduced bone density in HIV-infected women
    Dolan, SE
    Huang, JS
    Killilea, KM
    Sullivan, MP
    Aliabadi, N
    Grinspoon, S
    AIDS, 2004, 18 (03) : 475 - 483
  • [27] Low Bone Mineral Density in Vertically HIV-infected Children and Adolescents
    Jimenez, Beatriz
    Sainz, Talia
    Diaz, Laura
    Jose Mellado, Maria
    Luisa Navarro, Maria
    Rojo, Pablo
    Isabel Gonzalez-Tome, Maria
    Prieto, Luis
    Martinez, Jorge
    Isabel de Jose, Maria
    Tomas Ramos, Jose
    Angeles Munoz-Fernandez, Maria
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (06) : 578 - 583
  • [28] Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review
    de Carvalho, Erico Higino
    Gelenske, Thais
    Bandeira, Francisco
    Pessoa Militao de Albuquerque, Maria da Fatima
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2010, 54 (02) : 133 - 142
  • [29] Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients
    Carver, PL
    Fleisher, D
    Zhou, SY
    Kaul, D
    Kazanjian, P
    Li, C
    PHARMACEUTICAL RESEARCH, 1999, 16 (05) : 718 - 724
  • [30] IMPACT OF STRENGTH TRAINING ON BONE MINERAL DENSITY IN PATIENTS INFECTED WITH HIV EXHIBITING LIPODYSTROPHY
    Santos, Wlaldemir R.
    Santos, Walmir R.
    Paes, Pedro P.
    Ferreira-Silva, Isac A.
    Santos, Andre P.
    Vercese, Natan
    Machado, Dalmo R. L.
    de Paula, Francisco Jose A.
    Donadi, Eduardo A.
    Navarro, Anderson M.
    Fernandes, Ana Paula M.
    JOURNAL OF STRENGTH AND CONDITIONING RESEARCH, 2015, 29 (12) : 3466 - 3471